Loading clinical trials...
Loading clinical trials...
A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
Ibrutinib
Carfilzomib
+1 more
Locations
17
United States
City of Hope
Duarte, California, United States
University of California Los Angeles
Los Angeles, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
New York Presbyterian Hospital - Weill-Cornell
New York, New York, United States
Mount Sinai Hospital
New York, New York, United States
Start Date
December 1, 2013
Primary Completion Date
March 1, 2019
Completion Date
March 1, 2019
Last Updated
December 21, 2021
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Pharmacyclics LLC.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions